drugset / Trial / NCT06891742
Phase I Study of OriC902 in Treatment of Advanced HCC
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase I clinical study evaluating the safety, pharmacokinetics, and initial efficacy of a GPC3-targeted chimeric antigen receptor autologous T cell injection (OriC902) in GPC3-positive advanced hepatocellular carcinoma (HCC) subjects
Timeline
- Start
- 2025-02-24
- Primary completion
- 2027-12-31
- Completion
- 2028-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | OriC902 | Cell therapy | 1e+06 cells/kg | — |
| Subject | OriC902 | Cell therapy | 3e+06 cells/kg | — |
| Subject | OriC902 | Cell therapy | 6e+06 cells/kg | — |
| Subject | OriC902 | Cell therapy | 1e+07 cells/kg | — |